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Long-term risk of carotid restenosis in patients randomly 
assigned to endovascular treatment or endarterectomy in 
the Carotid and Vertebral Artery Transluminal Angioplasty 
Study (CAVATAS): long-term follow-up of a randomised trial
Leo H Bonati, Jörg Ederle, Dominick J H McCabe, Joanna Dobson, Roland L Featherstone, Peter A Gaines, Jonathan D Beard, Graham S Venables, 
Hugh S Markus, Andrew Clifton, Peter Sandercock, Martin M Brown, on behalf of the CAVATAS Investigators*
Summary
Background In the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS), early recurrent carotid 
stenosis was more common in patients assigned to endovascular treatment than it was in patients assigned to 
endarterectomy (CEA), raising concerns about the long-term eﬀ ectiveness of endovascular treatment. We aimed to 
investigate the long-term risks of restenosis in patients included in CAVATAS.
Methods 413 patients who were randomly assigned in CAVATAS and completed treatment for carotid stenosis 
(200 patients had endovascular treatment and 213 patients had endarterectomy) had prospective clinical follow-up at 
a median of 5 years and carotid duplex ultrasound at a median of 4 years. We investigated the cumulative long-term 
incidence of carotid restenosis after endovascular treatment and endarterectomy, the eﬀ ect of the use of stents on 
restenosis after endovascular treatment, risk factors for the development of restenosis, and the eﬀ ect of carotid 
restenosis on the risk of recurrent cerebrovascular events. Analysis was by intention to treat. This study is registered, 
number ISRCTN01425573.
Findings Severe carotid restenosis (≥70%) or occlusion occurred signiﬁ cantly more often in patients in the endovascular 
arm than in patients in the endarterectomy arm (adjusted hazard ratio [HR] 3·17, 95% CI 1·89–5·32; p<0·0001). The 
estimated 5-year incidence of restenosis was 30·7% in the endovascular arm and 10·5% in the endarterectomy arm. 
Patients in the endovascular arm who were treated with a stent (n=50) had a signiﬁ cantly lower risk of developing 
restenosis of 70% or greater compared with those treated with balloon angioplasty alone (n=145; HR 0·43, 0·19–0·97; 
p=0·04). Current smoking or a history of smoking was a predictor of restenosis of 70% or more (2·32, 1·19–4·54; 
p=0·01) and the early ﬁ nding of moderate stenosis (50–69%) up to 60 days after treatment was associated with the 
risk of progression to restenosis of 70% or more (3·76, 1·88–7·52; p=0·0002). The composite endpoint of ipsilateral 
non-perioperative stroke or transient ischaemic attack occurred more often in patients in whom restenosis of 70% or 
more was diagnosed in the ﬁ rst year after treatment compared with patients without restenosis of 70% or more 
(5-year incidence 23% vs 11%; HR 2·18, 1·04–4·54; p=0·04), but the increase in ipsilateral stroke alone was not 
signiﬁ cant (10% vs 5%; 1·67,  0·54–5·11).
Interpretation Restenosis is about three times more common after endovascular treatment than after endarterectomy 
and is associated with recurrent ipsilateral cerebrovascular symptoms; however, the risk of recurrent ipsilateral stroke 
is low. Further data are required from on-going trials of stenting versus endarterectomy to ascertain whether long-
term ultrasound follow-up is necessary after carotid revascularisation. 
Funding British Heart Foundation; UK National Health Service Management Executive; UK Stroke Association. 
Introduction
Atherosclerotic carotid artery stenosis is a main cause of 
transient ischaemic attack and stroke. In patients with 
recent cerebrovascular symptoms associated with severe 
carotid stenosis, the risk of recurrent stroke can be 
reduced by more than a half after carotid endarterectomy.1 
Endo vascular treatment of carotid stenosis by 
percutaneous transluminal balloon angioplasty or 
insertion of a stent is an alternative to endarterectomy. 
However, a recent meta-analysis found a higher risk of 
stroke or death within 30 days after endovascular 
treatment than after endarterectomy, with some 
uncertainty about this result, and endarterectomy has 
remained the treatment of choice for carotid stenosis.2 
The long-term eﬃ  cacy of endovascular treatment for 
preventing stroke is unknown. The Carotid and Vertebral 
Artery Transluminal Angioplasty Study (CAVATAS) was 
a large multicentre randomised trial with the aim of 
comparing endovascular treatment (angioplasty with or 
without stenting) with endarterectomy in patients with 
predominantly symptomatic moderate or severe carotid 
stenosis.3 The initial report from CAVATAS showed no 
diﬀ erence in the primary endpoint of disabling stroke or 
death, or in ipsilateral stroke in the ﬁ rst 3 years after 
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treatment. However, 1 year after treatment, severe 
stenosis or occlusion of the carotid artery was seen more 
often after endovascular treatment than after 
endarterectomy.4 Concern remained that the proportion 
of patients with restenosis after endovascular treatment 
would increase over time and that the high rate of 
restenosis might restrict the long-term eﬃ  cacy of 
endovascular treatment for stroke prevention. 
The long-term follow-up of patients in CAVATAS has 
recently been completed, 10 years after the last patient 
was randomised. In the analysis of clinical outcome 
events, which is reported in this issue,5 there was a 
non-signiﬁ cant diﬀ erence in the incidence of ipsilateral 
non-perioperative stroke or TIA that favoured 
endarterectomy (hazard ratio 1·29, 95% CI 0·78–2·14).
In this follow-up study, we analysed the available 
long-term carotid ultrasound data from CAVATAS with 
the following aims: to compare the cumulative long-term 
incidence of carotid restenosis after endovascular 
treatment and endarterectomy; to investigate the eﬀ ect of 
the use of stents on restenosis after endovascular 
treatment; to identify risk factors for the development of 
restenosis; and to investigate the eﬀ ect of carotid restenosis 
on the risk of recurrent cerebrovascular events. 
Methods
Patients
CAVATAS was a randomised, open, multicentre trial with 
outcome adjudication by investigators masked to 
treatment allocation. The trial methodology has been 
described in detail in the initial report.3 For the present 
study, we selected patients who had completed 
endovascular treatment or endarterectomy of the stenotic 
internal carotid artery and had follow-up data from 
carotid duplex ultrasound. The study population diﬀ ers 
from that in a previous report on residual and early 
recurrent stenosis in CAVATAS, which was restricted to 
ultrasound examinations done 1 month and 1 year after 
treatment and included both patients who had completed 
treatment and those with incomplete treatment.4 A few 
patients with stenosis of the common carotid artery were 
enrolled in CAVATAS, but these patients were excluded 
from this analysis owing to the absence of uniform 
criteria for grading stenosis of the common carotid artery 
with ultrasound. 
Procedures
In the ﬁ rst phase of the study, patients randomly assigned 
to endovascular treatment were treated by percutaneous 
transluminal angioplasty with balloon catheters. Stents 
became available in the second half of the recruitment 
period; collaborating interventionalists were subsequently 
permitted to use Wallstents, Palmaz, and Strecker stents 
at their discretion. Stents were most commonly deployed 
if the reduction in stenosis achieved with previous balloon 
angioplasty was unsatisfactory. In a few patients, primary 
stenting was done without ﬁ rst attempting full balloon 
dilatation. Endovascular treatment was deﬁ ned as 
complete if a balloon was dilated across the stenosis or a 
stent was successfully deployed.3 Collaborating surgeons 
used their preferred technique for endarterectomy, either 
with primary closure of the arteriotomy or closure with 
surgical patches. Completed endarterectomy was deﬁ ned 
as an operation in which removal of the atheromatous 
plaque and closure of the arteriotomy was achieved. 
The protocol recommended endovascular or surgical 
treatment for recurrent stenosis after initial treatment 
only if the patient developed relevant new symptoms. 
Asymptomatic restenosis was not deemed an indication 
for re-treatment because the risk of recurrent 
cerebrovascular events after restenosis was unknown. No 
recommendation as to the type of retreatment 
(endovascular or endarterectomy) was made. 
Patients in CAVATAS were examined at baseline by 
neurologically trained investigators not involved in the 
endovascular treatment or endarterectomy and followed 
up at 1 month, 6 months, and 1 year after treatment and 
annually thereafter. There was no predeﬁ ned maximum 
length of follow-up, but centres were encouraged to 
follow up patients for as long as the centre and individual 
patients were willing to do so. Follow-up ended in 2007, 
10 years after the end of recruitment. Outcome events, 
including stroke, transient ischaemic attack, and 
amaurosis fugax, were independently adjudicated by use 
of standard deﬁ nitions5 in the central trial oﬃ  ce by two 
investigators (LHB and JE) who were masked to treatment 
allocation. Amaurosis fugax was included in the category 
of transient ischaemic attack. In case of disagreement, a 
third independent investigator made the ﬁ nal 
adjudication. 
Carotid imaging before randomisation required either 
selective digital subtraction angiography (DSA) or 
consistent ﬁ ndings on carotid duplex ultrasound and 
non-invasive angiography (magnetic resonance 
angiography [MRA] or computer tomography angiography 
[CTA]). Assessment of the rate of restenosis after 
treatment was a predeﬁ ned objective of CAVATAS. The 
protocol included carotid duplex ultrasound follow-up 
1 year after treatment and every year thereafter. In many 
centres, additional ultrasound examinations were done at 
1 and 6 months after treatment. In the event of recurrent 
cerebro vascular events during follow-up, additional 
carotid imaging was done at the discretion of the local 
investigators.
The peak systolic velocities of the common carotid and 
the internal carotid arteries and the end diastolic velocity 
of the internal carotid artery were recorded with carotid 
duplex ultrasound and reported to the central trial oﬃ  ce. 
One investigator (LHB), who was masked to treatment 
allocation, ascertained the degree of stenosis during 
follow-up, on the basis of predeﬁ ned, standardised ﬂ ow 
velocity criteria, which equate well with the severity of 
carotid stenosis measured on catheter angiography with 
the North American Symptomatic Carotid Endarterectomy 
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Trial (NASCET) method (table 1).4,6 The severity of 
stenosis seen on carotid angiography (MRA, CTA, or 
DSA) done in addition to ultrasound for recurrent 
symptoms was measured according to the NASCET 
method. A second investigator made the ﬁ nal 
classiﬁ cation of stenosis when measurements from more 
than one imaging modality were conﬂ icting. Stenosis 
was classiﬁ ed as: not signiﬁ cant (0–49% stenosis), 
moderate (50–69%), severe (70–99%), or occluded (100%). 
Velocity measurements were not available for a few 
centres, and the degree of stenosis reported by the local 
ultrasonographer at the participating centre was used in 
these cases. 
The primary outcome of this analysis (≥70% restenosis) 
was deﬁ ned as any residual or recurrent severe stenosis 
or occlusion of the carotid artery detected at any stage 
during follow-up after completed treatment. The 
secondary outcome (≥50% restenosis) was deﬁ ned as 
any residual or recurrent moderate or severe carotid 
stenosis or occlusion after completed treatment. We 
compared the incidence of the primary and secondary 
outcomes between patients randomly assigned to 
endovascular treatment versus endarterectomy and 
between patients who were treated with balloon 
angioplasty alone (without use of a stent) and patients 
treated with a stent in those randomly assigned to 
endovascular treatment. Because the use of stents was 
not randomised in CAVATAS, the analysis of patients 
treated with stents and those treated with balloon 
angioplasty is a comparison of two subsets of patients in 
the endovascular treatment arm and is based on 
post-randomisation information (ie, which endovascular 
treatment technique the patient actually received).
We investigated whether the following baseline 
characteristics were independently associated with 
restenosis of 70% or more: age at randomisation, sex, 
smoking, hypertension, hypercholesterolaemia, 
diabetes, history of coronary heart disease, history of 
peripheral vascular disease, and the degree of ipsilateral 
carotid stenosis at randomisation according to the 
NASCET method. In a separate analysis, we assessed 
whether the moderate (50–69%) residual or early 
recurrent stenosis diagnosed up to 60 days after 
treatment was associated with long-term risk of 
restenosis of 70% or more.
To assess the association between restenosis and 
recurrent cerebrovascular events during long-term 
follow-up, we compared the incidence of the composite 
endpoint of ipsilateral stroke or transient ischaemic 
attack, and only ipsilateral stroke between patients with 
and without 70% or more restenosis diagnosed in the 
ﬁ rst year after treatment. Only cerebrovascular events 
that occurred after the ﬁ rst 1-year carotid duplex 
ultrasound that conﬁ rmed 70% or more restenosis or 
less than 70% restenosis were included. Events that 
occurred within 30 days of initial treatment were excluded 
because they were deﬁ ned as perioperative complications 
of treatment. To ascertain the natural risk of 
cerebrovascular events with restenosis, patients who had 
endovascular treatment or endarterectomy for recurrent 
stenosis after their initial treatment were censored at the 
time of retreatment.
Statistical analysis
Data analysis was primarily done according to the 
randomly assigned treatment (intention to treat). A 
second, per-protocol analysis, which excluded patients 
who did not receive their assigned treatment, was also 
done. The incidence of restenosis after stenting compared 
with angioplasty alone could only be calculated from the 
per-protocol analysis. To check whether the length of 
carotid duplex ultrasound follow-up was similar in both 
treatment arms, the time to censoring was compared by 
use of the log-rank test. When comparing the risks of 70% 
or more and 50% or more restenosis between the 
treatment groups, the exact date of restenosis was not 
known (ie, restenosis was only known to have occurred at 
some point between the previous normal ultrasound and 
the examination at which restenosis was diagnosed). Data 
in this form are known as interval-censored data and 
require appropriate analysis methods. Because the 
scheduled ultrasound examinations did not always take 
place at the planned times, and because some patients 
missed their scheduled appointments, an analysis method 
in which observation times can diﬀ er among individuals 
was used.7 This method assumes proportional hazards 
and is based on a non-linear model for a set of binary 
response variables (a generalised non-linear model). The 
resulting parameter estimates, such as the treatment 
eﬀ ect estimate, can be interpreted as log hazard ratios. 
For these models, patients without restenosis were 
censored at the time of their last carotid duplex ultrasound. 
Censoring was assumed to be non-informative. The 
proportionality of hazards was assessed by interactions 
with follow-up time periods. There was some suggestion 
that the hazard ratio of endovascular treatment versus 
carotid endarterectomy for the 50% or greater restenosis 
outcome might decrease over the course of the study, but 
PSV ICA (m/s) EDV ICA (m/s) PSV ICA/PSV CCA
0–29% <1·1 <0·4 <3·2
30–49% 1·1–1·3 <0·4 <3·2
50–59% >1·3–2·1 <0·4 <3·2
60–69% >1·3–2·1 0·4–1·1 3·2–4·0
70–79% >2·1 >1·1–1·4 >4·0
80–95% >2·1 >1·4 >4·0
96–99% String ﬂ ow String ﬂ ow String ﬂ ow
100% Occluded Occluded Occluded
PSV=peak systolic velocity. ICA=internal carotid artery. EDV=end diastolic velocity. 
CCA=common carotid artery. NASCET=North American Symptomatic Carotid 
Endarterectomy Trial.
Table 1: Duplex ultrasound velocity criteria equivalent to NASCET 
angiography measures used for grading the degree of carotid stenosis
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the test for non-proportionality of hazards was not 
signiﬁ cant (p=0·1). The hazard ratios and their 95% CIs 
throughout the follow-up period are reported. Life-table 
analyses were used to estimate the cumulative incidences 
of restenosis at the scheduled examination times after 
treatment, with predeﬁ ned interest in the incidences at 
1 year and 5 years. For the patients diagnosed with 
restenosis who were missing from the previous scheduled 
ultrasound examination, restenosis was assumed to have 
occurred during the life-table interval, half way between 
diagnosis and the last available normal ultrasound 
examination. Cumulative incidences for later than 5 years 
after treatment were not calculated because the patients 
who continued to have ultrasound follow-up was small. 
Multivariable generalised non-linear models that were 
adjusted for treatment were used to test whether 70% or 
more restenosis during follow-up was associated with the 
above deﬁ ned baseline covariates and early 50–69% 
stenosis. Hazard ratios calculated for restenosis were 
adjusted for age, sex, and the independent baseline 
predictors of restenosis identiﬁ ed in the multivariable 
model. Cox regression analysis was used to compare time 
until ipsilateral cerebrovascular events between patients 
with and without 70% or more restenosis detected within 
the ﬁ rst year after treatment (including ultrasound 
examinations done up to 1·5 years after treatment because 
the scheduled 1-year examinations did not always take 
place exactly 1 year after treatment) and were adjusted for 
allocated treatment, age, and sex. This study is registered, 
number ISRCTN01425573.
Role of the funding source
The study sponsors had no role in study design, data 
collection, data analysis, data interpretation, or the 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between March 1, 1992, and July 31, 1997, 504 patients 
were randomly assigned to endovascular treatment 
(n=251) or endarterectomy (n=253) by telephone or fax 
from the randomisation service at the Oxford Clinical 
Trials Unit. Figure 1 shows the trial proﬁ le. Of the 
patients randomly assigned to endovascular treatment, 
240 had initial treatment as allocated, six crossed over to 
endarterectomy, and ﬁ ve received neither endovascular 
treatment nor endarterectomy. Among the patients 
randomly assigned to endarterectomy, 246 received the 
treatment they were assigned, two crossed over to 
endovascular treatment, and ﬁ ve received neither of the 
two treatments. Endovascular treatment was not 
504 patients with conﬁrmed 
carotid stenosis
251 randomly assigned to 
endovascular treatment
200 analysed (intention 
to treat)
213 analysed (intention 
to treat)
240 received endovascular 
treatment
195 analysed (per protocol)
 145 had just angioplasty
 50 had stenting
212 analysed (per protocol)
 27 did not complete 
  endovascular treatment
 1 had common carotid 
   artery stenosis
 17 did not have ultrasound 
  follow-up
1 did not have ultrasound 
follow-up
 1 had common carotid 
  artery stenosis
 33 did not have ultrasound 
  follow-up
1 did not complete 
endovascular treatment
6 received carotid 
endarterectomy
246 received carotid 
endarterectomy 
2 received endovascular 
treatment
3 died before treatment
1 had stroke
1 treated medically
1 died before treatment
1 had stroke
3 treated medically
253 randomly assigned to 
carotid endarterectomy
Figure 1: Trial proﬁ le
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completed in 27 of the patients assigned to this treatment 
and in one patient who was allocated to endarterectomy 
but crossed over to the other treatment arm. 
Endarterectomy was completed in each patient who had 
surgery. The reasons for not receiving the randomly 
allocated treatment or for incomplete treatment were 
speciﬁ ed in the initial report.3 One patient in each 
treatment arm was treated for stenosis of the common 
carotid artery and was thus excluded from the present 
analysis. Among the patients who completed treatment, 
18 patients in the endovascular group and 33 patients in 
the endarterectomy group did not have carotid duplex 
ultrasound follow-up. Therefore, the intention-to-treat 
analysis of those patients who completed treatment 
comprised 200 patients who had endovascular treatment 
and 213 patients who had endarterectomy; the 
per-protocol analysis comprised 195 patients treated 
with the endovascular approach (angioplasty alone 
n=145; stenting n=50) and 212 patients treated with 
endarterectomy.
Baseline clinical characteristics of patients included in 
the present analysis of restenosis were similar to the 
whole population of CAVATAS and there were no 
signiﬁ cant diﬀ erences between those assigned to 
endovascular treatment and those assigned to 
endarterectomy (table 2). More than 90% of patients had 
a cerebrovascular event in the territory of the ipsilateral 
carotid artery within 6 months before randomisation. 
The duration of the carotid duplex ultrasound follow-up 
(median 4·0 [IQR 1·9–5·4] years in the endovascular arm 
vs 4·1 [1·3–5·5] years in the surgery arm) and clinical 
follow-up (5·0 [3·0–6·2] years vs 5·0 [2·9–6·1] years) 
were similar in the two arms, and there was no evidence 
of a diﬀ erence in time to censoring (log rank p=0·9). In 
the endovascular arm, patients who were treated with 
stenting were less likely to have a history of peripheral 
vascular disease than were patients treated with 
angioplasty alone (4 of 50 [8%] vs 38 of 145 [26%]; 
p=0·005). Other clinical characteristics were similar 
between the two endovascular treatment subgroups.
The primary outcome (≥70% restenosis) occurred 
signiﬁ cantly more often in patients who had endovascular 
treatment than in patients who had endarterectomy 
(53 vs 20 patients [adjusted HR 3·17, 95% CI 1·89–5·32; 

















Age (years) 67·0 (8·4) 67·0 (8·4) 66·5 (8·5) 66·6 (9·2) 66·6 (8·1) 67·4 (8·3) 
Men 352 (70%) 286 (69%) 142 (71%) 33 (66%) 104 (72%) 144 (68%)
Vascular risk factors
Smoking (past or present) 383 (76%) 307 (74%) 151 (76%) 36 (72%) 114 (79%) 156 (73%)
History of hypertension 276 (55%) 224 (54%) 103 (52%) 24 (48%) 77 (53%) 121 (57%)
History of hypercholesterolaemia 129 (26%) 107 (26%) 53 (27%) 13 (26%) 40 (28%) 54 (25%)
History of diabetes 67 (13%) 57 (14%) 28 (14%) 8 (16%) 20 (14%) 29 (14%)
History of coronary heart disease 187 (37%) 155 (38%) 78 (39%) 19 (38%) 57 (39%) 77 (36%)
History of peripheral vascular disease 111 (22%) 86 (21%) 42 (21%) 4 (8%)‡ 38 (26%)‡ 44 (21%)
Ipsilateral cerebrovascular events within 
6 months before randomisation
452 (90%) 394 (95%) 192 (96%) 48 (96%) 139 (96%) 202 (95%)
Mean degree of ipsilateral carotid stenosis before 
treatment§
77·2% (14·2) 76·8% (14·3) 77·0% (14·2) 77 ·3% (12·1) 76·8% (15·1) 76·6% (14·5)
Median duration of clinical follow-up (years) 5·0 (2·6–6·1) 5·0 (2·9–6·1) 5·0 (3·0–6·2) 5·0 (2·2–6·5) 5·0 (3·0–6·1) 5·0 (2·9–6·1)
Median duration of ultrasound follow-up (years) ·· 4·0 (1·8–5·5) 4·0 (1·9–5·4) 3·2 (1·0–5·3) 4·0 (2·0–5·4) 4·1 (1·3–5·5)
Data are mean (SD), number (%), or median (IQR) at the time of randomisation. EVT=endovascular treatment. CEA=carotid endarterectomy. ··=not available. *Numbers are 
intention-to-treat analysis of restenosis of patients randomly assigned to endovascular therapy versus patients randomly assigned to endarterectomy. †Numbers are non-randomised 
per-protocol comparison of restenosis of patients who received endovascular treatment by stenting versus patients who received endovascular treatment by angioplasty alone. 
‡p<0·005. §Degree of stenosis measured on angiography at study entry according to NASCET (North American Symptomatic Carotid Endarterectomy Trial) method.6
Table 2: Clinical characteristics
Endovascular treatment (n=200) Endarterectomy (n=213)
≥70% restenosis
Number of patients with outcome 53 20
Cumulative 1-year incidence* 21·7% (3·0) 7·5% (1·9)
Cumulative 5-year incidence* 30·7% (3·7) 10·5% (2·4)
Unadjusted hazard ratio† 3·14, 1·87–5·26‡
Adjusted hazard ratio† 3·17, 1·89–5·32‡
≥50% restenosis
Number of patients with outcome 109 59
Cumulative 1-year incidence* 48·5% (3·6) 20·7% (2·9)
Cumulative 5-year incidence* 58·6% (3·9) 31·5% (3·5)
Unadjusted hazard ratio† 2·57, 1·87–3·53‡
Adjusted hazard ratio† 2·58, 1·87–3·55‡
Data are number, cumulative incidence (SE), or hazard ratio, 95% CI. *Cumulative incidence of restenosis estimated 
from life-table analysis. †Restenosis after endovascular treatment compared with carotid endarterectomy to the end 
of available follow-up (generalised non-linear model: unadjusted and adjusted for sex, age, and smoking). ‡p<0·0001.
Table 3: Carotid restenosis after endovascular treatment compared with endarterectomy
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p<0·0001]; table 3, ﬁ gure 2). 1 and 5 years after treatment, 
the cumulative incidences of 70% or greater restenosis 
were 21·7% (SE 3·0) and 30·7% (3·7), respectively, in the 
endovascular arm and 7·5% (1·9) and 10·5% (2·4), 
respectively, in the surgery arm.
The secondary outcome (≥50% restenosis) also occurred 
more frequently in the endovascular arm than in the 
surgery arm (109 vs 59; adjusted HR 2·58, 95% CI 
1·87–3·55; p<0·0001). The cumulative 1-year and 5-year 
incidences of 50% or more restenosis were 48·5% 
(SE 3·6) and 58·6% (3·9), respectively, in the endovascular 
arm, compared with 20·7% (2·9) and 31·5% (3·5), 
respectively, in the endarterectomy group. 
Similar results were obtained in the secondary per-
protocol analysis: adjusted HR 3·40 (95% CI 2·10–5·77) 
for 70% or more restenosis and 2·72, (1·97–3·75) for 
50% or more restenosis after endovascular treatment 
compared with endarterectomy. 
Of the patients who were assigned to endovascular 
treatment, the risks of 70% or more restenosis (adjusted 
HR 0·43, 0·19–0·97; p=0·04) and 50% or more restenosis 
(0·37, 0·21–0·62; p=0·0003) were signiﬁ cantly lower in 
those patients treated with a stent than in those treated 
by angioplasty alone (table 4, ﬁ gure 2). 
Of all the covariates tested at baseline, smoking (either at 
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Angioplasty
Stenting
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HR 3·17, 95% CI 1·89–5·32 HR 2·58, 95% CI 1·87–3·55
HR 0·43, 95% CI 0·19–0·97 HR 0·37, 95% CI 0·21–0·62
Figure 2: Cumulative incidence of restenosis estimated from life-table analysis 
Data are the cumulative incidence of restenosis after endovascular treatment compared with endarterectomy (A,B), and for stenting compared with balloon angioplasty alone 
(C,D), respectively, to the end of available follow-up, from generalised non-linear models. (A,C) 70% or more restenosis. (B,D) 50% or more restenosis. Vertical bars are SE.
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of 70% or more restenosis (HR 2·32, 95% CI 1·19–4·54; 
p=0·01 [adjusted for treatment in current or ex-smokers 
compared with those who never smoked]). There was no 
signiﬁ cant interaction between treatment and the eﬀ ect of 
smoking on restenosis (p=0·86). Residual or recurrent 
stenosis of between 50–69% seen on early ultrasound at 
any time up to 60 days after treatment was associated with 
a signiﬁ cant increase in the risk of subsequent progression 
to 70% or more restenosis (HR 3·76, 95% CI 1·88–7·52; 
p=0·0002) compared with 0–49% stenosis seen on early 
carotid duplex ultrasound, adjusted for treatment. There 
was no signiﬁ cant interaction between treatment and the 
eﬀ ect of early moderate stenosis on progression to severe 
restenosis or occlusion (p=0·91).
The incidence of ipsilateral non-perioperative stroke or 
transient ischaemic attack was signiﬁ cantly higher in 
patients with 70% or more restenosis that was diagnosed 
within the ﬁ rst year after treatment compared with those 
who had less than 70% restenosis in the ﬁ rst year. 10 of 
52 patients (cumulative 5-year incidence 22·7%) with 70% 
or more restenosis had subsequent ipsilateral cerebro-
vascular events compared with 35 of 344 patients (10·9%) 
with less than 70% restenosis (adjusted HR 2·18, 95% CI 
1·04–4·54; p=0·04; table 5, ﬁ gure 3). In three patients 
without 70% or more restenosis in the ﬁ rst year who had 
an ipsilateral cerebrovascular event, carotid duplex 
ultrasound done after the event detected severe restenosis. 
There was a higher incidence of ipsilateral stroke in 
patients with 70% or more restenosis (four patients [9·7%]) 
compared with patients without 70% or more restenosis 
(17 patients [5·4%]) but the diﬀ erence was not statistically 
signiﬁ cant (1·67, 0·54–5·11; p=0·4).
Seven patients in the endovascular arm had repeat 
endovascular treatment for restenosis (6 patients who 
were symptomatic and 1 patient who was asymptomatic). 
One of these patients had an ipsilateral non-disabling 
stroke during the procedure. In the endarterectomy arm, 
one patient had repeat endarterectomy for symptomatic 
restenosis and one patient had repeat endarterectomy for 
asymptomatic restenosis; these were done without 
complications.
Discussion
This study provides several key ﬁ ndings: the long-term 
risk of developing severe (≥70%) carotid restenosis or 
occlusion was about three times higher after 
endovascular treatment than it was after endarterectomy; 
smoking and moderate residual or early recurrent 
stenosis were independent predictors of severe carotid 
restenosis or occlusion during follow-up; and severe 
carotid restenosis or occlusion was associated with an 
increased risk of ipsilateral cerebrovascular events 
during follow-up.
CAVATAS was a large randomised trial to assess the 
long-term risk of restenosis after revascularisation of 
symptomatic carotid stenosis. The previous large trials of 
endarterectomy for symptomatic stenosis (ie, NASCET 
and the European Carotid Surgery Trial [ECST]) did not 
include carotid ultrasound follow-up.6,8 In CAVATAS, 31% 
of patients in the endovascular group developed severe 
(≥70%) carotid restenosis or occlusion by the ﬁ fth year 
after treatment compared with only 11% of the patients 
treated with endarterectomy. The secondary outcome 
(moderate or worse [≥50%] restenosis) was estimated to 
occur in 59% of patients in the ﬁ rst 5 years after 
endovascular treatment compared with 32% of patients 
in the ﬁ rst 5 years after endarterectomy. The cumulative 
long-term incidence of restenosis seen in the 
endarterectomy arm of CAVATAS was similar to that 
seen in case series, in which incidences of up to 9% for 
severe restenosis or occlusion at 5 years and up to 32% 
Stenting (n=50) Angioplasty (n=145)
≥70% restenosis 
Number of patients with outcome 7 46
Cumulative 1-year incidence* 13·1% (5·0) 25·3% (3·7)
Cumulative 5-year incidence* 16·6% (5·9) 36·2% (4·5)
Unadjusted hazard ratio† 0·41, 0·19–0·92‡
Adjusted hazard ratio† 0·43, 0·19–0·97§
≥50% restenosis 
Number of patients with outcome 16 93
Cumulative 1-year incidence* 23·0% (6·1) 58·8% (4·2)
Cumulative 5-year incidence* 36·6% (8·1) 68·1% (4·3)
Unadjusted hazard ratio† 0·36, 0·21–0·61¶ 
Adjusted hazard ratio† 0·37, 0·21–0·62||
Data are number, cumulative incidence (SE), or hazard ratio, 95% CI. *Cumulative incidence of restenosis estimated 
from life-table analysis. †Restenosis after stenting compared with balloon angioplasty alone to the end of available 
follow-up (generalised non-linear model: unadjusted and adjusted for sex, age, and smoking). ‡p=0·03. §p=0·04. 
¶p=0·0002. ||p=0·0003.
Table 4: Carotid restenosis after endovascular treatment with stenting compared with balloon 
angioplasty alone 
≥70% restenosis (n=52) <70% restenosis (n=344)
Ipsilateral stroke or transient ischaemic attack
Number of patients with endpoint 10 35
Cumulative 5-year incidence* 22·7% (6·4) 10·9% (1·9)
Unadjusted hazard ratio† 2·19, 1·08–4·43‡
Adjusted hazard ratio† 2·18, 1·04–4·54§ 
Ipsilateral stroke
Number of patients with endpoint 4 17
Cumulative 5-year incidence* 9·7% (4·7) 5·4% (1·4)
Unadjusted hazard ratio† 1·73, 0·58–5·16¶
Adjusted hazard ratio† 1·67, 0·54–5·11||
Data are number, cumulative incidence (SE), or hazard ratio, 95% CI. *Cumulative incidence of events estimated from 
Kaplan–Meier analysis. †Cox hazard ratio for ipsilateral cerebrovascular events during follow-up in patients with 70% or 
more restenosis in the ﬁ rst year after treatment compared with patients with less than 70% restenosis in the ﬁ rst year 
after treatment to the end of available follow-up: unadjusted and adjusted for treatment, sex, and age. Only events 
that occurred after the ﬁ rst ultrasound examination to show 70% or more stenosis or less than 70% restenosis are 
included. ‡p=0·03. §p=0·04. ¶p=0·3. ||p=0·4.
Table 5: Ipsilateral non-perioperative cerebrovascular events during follow-up in patients with 70% or 
more restenosis compared with patients with less than 70% restenosis diagnosed in the ﬁ rst year after 
treatment
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for moderate or worse restenosis at 7 years after treatment 
were reported.9–12
Most of the patients randomly assigned to endovascular 
treatment in CAVATAS had angioplasty without stents. 
In the endovascular arm, the long-term incidences of 
70% or more and 50% or more restenosis were lower 
after stenting than they were after balloon angioplasty 
alone. However, restenosis among patients who had a 
stent in CAVATAS was still more common than it was in 
case series of primary stenting, which have reported 
moderate restenosis in up to 16% of patients and severe 
restenosis in 6% of patients at 5 years.13–15 This might 
indicate better ascertainment of the restenosis outcome 
within the context of a clinical trial and highlights 
diﬀ erences in patient selection, stenting technique (in 
CAVATAS, most stenting procedures were done after 
balloon dilatation was attempted), and ultrasound criteria 
for grading restenosis. Our study therefore provides some 
evidence that stenting might be superior to angioplasty 
alone for the prevention of restenosis. The investigators in 
one trial that compared primary stenting with 
endarterectomy have published the incidence of carotid 
restenosis after a comparatively short follow-up period: the 
2-year cumulative risk of severe restenosis or occlusion 
was 11% after stenting compared with 5% after 
endarterectomy.16 Long-term follow-up data on restenosis 
from recent trials of primary stenting versus 
endarterectomy are needed to assess the long-term eﬃ  cacy 
of carotid stenting for the prevention of restenosis.17–19
Restenosis up to about 2 years after endarterectomy is 
commonly attributed to neointimal hyperplasia, whereas 
recurrent atherosclerosis is thought to cause later 
restenosis.20–22 Neointimal hyperplasia and smooth 
muscle cell proliferation have also been seen in a patient 
in CAVATAS who had symptomatic restenosis after 
endovascular treatment.23 This observation, and the fact 
that in both arms of CAVATAS most restenoses occurred 
within the ﬁ rst year of treatment, suggests that similar 
mechanisms are involved in restenosis after endovascular 
treatment and endarterectomy.
We found that smoking at study entry or past smoking 
was an independent predictor of restenosis. There was 
no signiﬁ cant interaction between treatment received 
and smoking for the prediction of restenosis, suggesting 
that smoking had a similar eﬀ ect in both treatment arms. 
Smoking has previously been indentiﬁ ed as a predictor 
of restenosis after endarterectomy.21 Smoking did not 
predict restenosis after carotid stenting in previous case 
series,24–26 but these studies had median follow-up times 
of only 2 years or less. Additionally, patients in whom 
moderate residual or early recurrent stenosis was found 
within 60 days of treatment were at signiﬁ cantly elevated 
risk for progression to severe restenosis or occlusion 
during follow-up compared with patients without 
signiﬁ cant early stenosis. These observations might be 
helpful when selecting patients for long-term ultrasound 
follow-up.
Severe carotid restenosis or occlusion diagnosed within 
the ﬁ rst year after treatment was associated with an 
increased risk of subsequent ipsilateral cerebrovascular 
events (ipsilateral stroke or transient ischaemic attack) 
during long-term follow-up. There was no signiﬁ cant 
increase in the risk of ipsilateral stroke in patients with 
70% or more restenosis compared with those with less 
than 70% restenosis; however, owing to the small number 
of patients that reached this endpoint, the conﬁ dence 
interval for the estimated hazard ratio was wide. As 
reported in the companion article on the long-term 
clinical outcome of CAVATAS,5 there were more patients 
with non-perioperative ipsilateral stroke or transient 
ischaemic attack (HR 1·29, 95% CI 0·78–2·14) and more 
patients with non-perioperative ipsilateral stroke (1·22, 
0·59–2·54) in the endovascular arm than there were in 
the endarterectomy arm during follow-up, although these 
 52 45 36 26 22 14 
 344 305 267 234 190 133
 52 47 40 31 27 15 
 344 312 277 241 201 143
Time after restenosis (years)
70% or more restenosis
Less than 70% restenosis
Number at risk
70% or more restenosis
Less than 70% restenosis
Number at risk
70% or more restenosis
Less than 70% restenosis
HR 2·18, 95% CI 1·04–4·54
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Figure 3: Kaplan–Meier estimates of ipsilateral stroke or transient 
ischaemic attack
(A) Ipsilateral stroke or transient ischaemic attack. (B) Ipsilateral stroke. Hazard 
ratio calculated from adjusted Cox hazard ratio for ipsilateral cerebrovascular 
events during follow-up in patients with 70% or more restenosis in the ﬁ rst year 
after treatment compared with patients with less than 70% restenosis in the ﬁ rst 
year after treatment to the end of available follow-up. Time is from the ﬁ rst 
ultrasound examination done within the ﬁ rst year after treatment that 
conﬁ rmed 70% or more restenosis or less than 70% restenosis.
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diﬀ erences were not statistically signiﬁ cant. The increase 
in events in the endovascular arm might be partly 
explained by the high incidence of restenosis after 
endovascular treatment. 
Because more than half of the recurrent cerebrovascular 
symptoms that occurred in patients with severe restenosis 
were transient, and because of the small number of 
outcome events, our data do not support routine elective 
carotid reinterventional treatment for asymptomatic 
severe carotid restenosis after endovascular treatment or 
endarterectomy. Any decision on potential reintervention 
in patients with asymptomatic severe carotid restenosis 
seen on routine carotid duplex ultrasound or angiographic 
screening should take into account the low risk of 
ipsilateral stroke in these patients (about 2% per year in 
our study).
Our study has several limitations. Owing to ﬁ nancial 
constraints and the restricted availability of ultrasound at 
the beginning of the trial, ultrasound follow-up was not 
available or was only done at 1 year after treatment at 
some centres. However, at the centres that recruited the 
most patients, annual ultrasound follow-up was usually 
continued after 1 year, and the median length of follow-up 
in CAVATAS is similar to that reported in open registries 
of the long-term risk of carotid restenosis. Therefore, the 
performance of ultrasound follow-up and its duration 
primarily depended on the centre where the patient was 
randomly assigned, rather than selection criteria at the 
patient level. Because equal proportions of patients were 
randomly assigned to each arm at the centres, any 
concerns about selection bias in the comparison of 
restenosis between treatments might be reduced. Stenting 
in the endovascular group was not randomly assigned in 
the trial, and only a few patients were treated with stents. 
Although the baseline characteristics were similar in 
those patients treated with and those treated without 
stents (with the exception of a history of peripheral artery 
disease), diﬀ erences in unmeasured risk factors might 
have been present. Additionally, most of the patients 
treated with stents received them after balloon angioplasty 
had not reduced the degree of stenosis suﬃ  ciently. The 
primary carotid stenosis in these patients might therefore 
have diﬀ ered from the stenosis in the patients in whom 
balloon angioplasty was successful, in a way that might 
have systematically altered their risk of restenosis. The 
strength of evidence from CAVATAS with regard to the 
eﬃ  cacy of stenting for preventing restenosis compared 
with angioplasty alone is therefore limited. Without 
broadly accepted criteria for ultrasound of stented carotid 
arteries, and for reasons of consistency with previous 
reports from CAVATAS, the same ultrasound criteria 
were applied in those patients treated with and without 
stents. This approach might have led to the overestimation 
of restenosis in the patients who received stents because 
of reduced compliance in the vessel wall.
Our study was underpowered to detect any eﬀ ect of 
carotid restenosis on ipsilateral stroke. Optimum medical 
treatment has improved since CAVATAS was designed. 
In particular, the use of lipid-lowering therapy in patients 
with symptomatic carotid artery stenosis is likely to have 
increased in recent years, and antiplatelet treatment 
regimens to be given around the time of stenting have 
been developed. These factors might possibly inﬂ uence 
the risk of restenosis after treatment, and information on 
lipid-lowering therapy was not systematically collected in 
CAVATAS. Finally, primary stenting has replaced balloon 
angioplasty as the endovascular treatment of choice for 
severe carotid stenosis. 
In conclusion, restenosis is about three times more 
common after endovascular treatment than it is after 
endarterectomy and seems to cause recurrent 
cerebrovascular events. More data from ongoing 
randomised trials that compare primary carotid stenting 
with endarterectomy are needed to assess whether 
modern stenting techniques are as eﬀ ective as  surgery 
for preventing restenosis in the long term and to 
determine accurately the relation between restenosis and 
recurrent stroke over time. In particular, whether patients 
treated with endovascular methods require long-term 
follow-up with carotid duplex ultrasound to detect 
restenosis before it becomes symptomatic remains 
uncertain.
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